Skyrizi
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation
August 21, 2019Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma
AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis
April 24, 2019Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …
Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications
March 27, 2019Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
